MedTrace Logo

Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy

NCT01319669 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-03-03

No results posted yet for this study

Summary

To assess the efficacy and safety of administration of rhTPO at different time in the treatment of thrombocytopenia caused by first-line GC/GP regimen for non small cell lung cancer (NSCLC)

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

recombinant human thrombopoietin

Recombinant human thrombopoietin injection in 15000U/ml/amp.

Sponsors & Collaborators

  • Chinese Society of Lung Cancer

    lead OTHER

Principal Investigators

  • Yi-Long Wu, Professor · Guangdong Provincial People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01319669 on ClinicalTrials.gov